Connect to share and comment

Halozyme halts trial of drug delivery system, shares slump

By Natalie Grover (Reuters) - Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent. The biotechnology company said it halted enrollment and patient dosing as a "precautionary measure" following the recommendation of an independent safety committee.

Risk of dying from cancer down 20 percent: US study

The risk of dying from cancer in the United States has declined 20 percent over the past two decades, according to the American Cancer Society's annual report out Tuesday. However, cancer, a complex disease that has largely eluded attempts at a cure, will remain a top killer in 2014, taking some 1,600 US lives per day, it warned. The group's yearly report is based on data from the Centers for Disease Control and Prevention, the National Cancer Institute and the National Center for Health Statistics.

Risk of dying from cancer down 20 percent: US study

The risk of dying from cancer in the United States has declined 20 percent over the past two decades, according to the American Cancer Society's annual report out Tuesday. However, cancer, a complex disease that has largely eluded attempts at a cure, will remain a top killer in 2014, taking some 1,600 US lives per day, it warned. The group's yearly report is based on data from the Centers for Disease Control and Prevention, the National Cancer Institute and the National Center for Health Statistics.

Pollution poses health, economic and national security problems for China

Beijing, Nov 5 (EFE).- Air pollution, which affects many cities and regions in China, poses health, economic and national security problems for the Asian nation, experts said in reports released Tuesday. The studies were released as reports surfaced that an 8-year-old girl had become China's youngest lung cancer patient, with doctors blaming her condition on the high levels of air pollution to which she was exposed in her short life.

Cancer costs EU $170 bln annually

Cancer cost the then 27 countries of the European Union 126 billion euros ($170.1 billion) in 2009, according to a study published on Monday. The bill mainly comprised 51 billion euros in costs for health-scare systems, including drugs; 23 billion euros in unpaid care provided by friends and relatives of people with cancer; and 52 billion euros in lost productivity due to premature deaths and illness. Britain, France, Germany and Italy accounted for most than two-thirds of the cost.

ArQule up on hope for lung cancer drug revival

(Reuters) - ArQule Inc shares jumped 19 percent on hopes that additional data from a discontinued trial could revive its experimental drug, tivantinib, as a treatment for lung cancer. Last October, ArQule and Daiichi Sankyo Inc stopped a late-stage trial of tivantinib to treat lung cancer after determining that the drug did not improve patient survival.

Survivors of childhood cancer prone to adult illness

Patients who successfully battled cancer during childhood face an extraordinarily high rate of chronic illness during their grown-up years, according to study published Tuesday. The research released by the Journal of the American Medical Association (JAMA) tracked 1,700 adult survivors of childhood cancer, and found that the vast majority were combating one or more chronic ailments.

Latin America threatened with cancer epidemic

Latin America faces a cancer epidemic, scientists warned Friday as they pressed for urgent action to reduce tobacco use and obesity and allocate more resources to control the disease. The researchers spoke at the Latin American Cooperative Oncology Group (LACOG) 2013 conference at which they unveiled a groundbreaking study on soaring cancer cases in the region.

Latin America threatened with cancer epidemic

Latin America faces a cancer epidemic unless governments act quickly to improve health care systems and treat the poor, scientists said. The researchers pointed to around 13 deaths for every 22 cancer cases in the region, compared to around 13 deaths for every 37 cases in the United States and around 13 deaths for every 30 cases in Europe. The main reason, according to the study published in the British journal The Lancet Oncology, is that too many people are diagnosed with cancer at a late stage when the disease is much harder to treat and more likely to kill.

ANALYSIS-In war against cancer, progress is in the eye of the beholder

* Deaths rates fell an average 1.5 percent per year, 2000 to 2009 * In men, mortality rose for melanoma, cancers of liver and pancreas * Much of improvement in incidence, mortality reflects less smoking By Sharon Begley NEW YORK, Jan 7 (Reuters) - As the United States enters the fifth decade of its "war on cancer," deaths continue to decline, according to an exhaustive report based on official data released on Monday.
Syndicate content